Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

Pulmonary hypertension (PH) is a rare, progressive, debilitating condition characterised by elevated pulmonary artery ...

Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...

A schematic illustration depicting the 3 major hemodynamic causes of pulmonary hypertension and their intersections ... Once the diagnosis of PH is made, the absolute level of PAP elevation deserves ...

Background Pulmonary hypertension (PH) is a progressive cardiopulmonary condition associated with increased morbidity and ...

Among patients with pulmonary arterial hypertension treated with selexipag, the 10-year survival rate was 60%, according to ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...

In a significant step towards advancing specialized cardiopulmonary care, Kauvery Hospital, Vadapalani, inaugurated its ...